Search results
Your search for XIST returned no results
Showing 1546 to 1556 of 1556 results for list
Showing 1546 to 1556 of 1556 results for list
Digital services to enable easier access to weight management support
Four digital programmes can be used to help the NHS deliver specialist weight management services to support the use of medication in England
Our updated guideline to improve the diagnosis of endometriosis
The guideline makes new recommendations and updates existing ones on diagnosing and managing a condition that affects approximately 1.5 million women of reproductive age in the UK.
Consultation on NHS England proposals for a phased launch of obesity injection
Proposals for a phased launch of the obesity injection tirzepatide have been set out, as a consultation begins.
"Tell me and I forget. Teach me and I remember. Involve me and I learn." Benjamin Franklin.
Starting with the end in mind - the Innovative Licensing and Access Pathway
The Innovative Licensing and Access Pathway (ILAP) will smooth the process by which innovative new medicines are developed, speeding their progression from clinical trial through to the NHS, bringing significant benefits to patients.
More than 20 pieces of draft and final guidance on a range of medicines and medical conditions were published during the pre-election period.
Thousands of people living with obesity are set to benefit from a new drug which has helped those using it to reduce their weight by more than 10 per cent.
Patients in England with severe beta-thalassaemia will be amongst the first in Europe to benefit from one-time gene therapy exagamglogene autotemcel.
People at risk of severe COVID-19 to have access to antiviral Paxlovid
A further 1.4 million people who have an increased risk for progression to severe COVID-19 will be eligible for Paxlovid if they test positive.
NICE collaborates with international partner agencies to streamline the confidential marking process
NICE, the Canadian Agency for Drugs and Technologies in Health and the US’s Institute for Clinical and Economic Review changes the way information about health technologies is handled to streamline processes and increase transparency.
NICE recommends olaparib for early breast cancer and metastatic prostate cancer
Deals for anti-cancer medicine olaparib have paved the way for hundreds to benefit as NICE recommends it for some types of early breast cancer and advanced prostate cancer.